Surrozen (SRZN) Net Equity Issued and Repurchased (2021 - 2026)
Surrozen (SRZN) posted quarterly Net Equity Issued and Repurchased of $50.0 million for Q1 2026, down 34.54% year-over-year from $76.4 million in Q1 2025, and up 1328.16% quarter-over-quarter from $3.5 million in Q4 2025.
Surrozen (SRZN) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Surrozen's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $50.0 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 34.54% year-over-year to $50.0 million; the TTM figure through Mar 2026 stood at $48.3 million (down 47.73% YoY), while the FY2025 annual figure was $74.7 million, up 365.64% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $50.0 million, up from $3.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $76.4 million in Q1 2025, with the low at -$5.2 million in Q2 2025.
- The 3-year median for Net Equity Issued and Repurchased is $9.8 million (2024), against an average of $23.5 million.
- The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased plunged 132.32% in 2025, then plunged 34.54% in 2026.
- Surrozen's Net Equity Issued and Repurchased stood at -$1000.0 in 2024, then surged by 350200.0% to $3.5 million in 2025, then soared by 1328.16% to $50.0 million in 2026.
- Business Quant data shows SRZN's Net Equity Issued and Repurchased at $50.0 million in Q1 2026, $3.5 million in Q4 2025, and -$5.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.90 Mn |
| Jun 30, 2026 | -26.90 Mn |
| Mar 31, 2026 | 50.00 Mn |
| Mar 31, 2026 | 50.00 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Jun 30, 2025 | -5.19 Mn |
| Jun 30, 2025 | -5.19 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 16.04 Mn |
| Jun 30, 2024 | 16.04 Mn |
| Dec 31, 2021 | 125,000.00 |
| Dec 31, 2021 | 125,000.00 |